

# The Script – January/February/March 2025

## **Kroger/Pick-n-Save Pharmacy Update**

Beginning February 5, 2025, Kroger (which includes retail locations of Pick ‘n Save, Metro Market and Cops) was added back in to Network Health’s Medicare pharmacy network as a standard retail pharmacy for 2025. Our online pharmacy look-up tool now reflects this change. For our commercial line of business, we anticipate Kroger being a contracted provider in 2025, but do not have a specific time frame.

---

## **Network Health Pharmacy Team Supports our Medicare Advantage Members**

Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) offers incredibly low prices on hundreds of commonly prescribed medications. Cost Plus Drugs is a different pharmacy model, ensuring the lowest prices by negotiating directly with the manufacturer and passing the savings directly on to the member. To keep costs low, Cost Plus Drugs has a unique and convenient set-up and is available online only as a preferred mail order pharmacy option. Members can visit [costplusdrugs.com](https://costplusdrugs.com) to get started by clicking **Sign Up**. Instructions for how to send a prescription can be found at [costplusdrugs.com/contact-your-doctor/](https://costplusdrugs.com/contact-your-doctor/). It is important that you include the patient’s email address on the prescriptions being sent over to Cost Plus Drugs.

1. Network Health Medicare Advantage members can save up to 70% or more on thousands of popular prescription medications by using Mark Cuban Cost Plus Drugs. [You can view which medications are included, and at what price, by clicking here.](#) To sign up, members should visit the above website, search their medications and click “Sign Up.” Members can have their prescriptions sent to Cost Plus Drugs by following [the instructions here](#). When sending over prescriptions, please ensure your patient’s email address included on the prescription, when sending over.
  2. In collaboration with Froedtert Home Delivery, members can have their medications shipped directly to their door, saving the costs and time associated with going to pick them up.
  3. Network Health's pharmacy team helps members save every day through Medication Therapy Management (MTM). By offering a Comprehensive Medical
-

Review (CMR), our pharmacists are able to recommend biosimilars or generics that avoid the high, and increasing, costs of brand name medications.

We've created a special landing page outlining these three strategies and empowering members to research medication, sign up for Froedtert Home Delivery or contact a Network Health pharmacist for a medications review.

[Learn More](#)

### New Mail Order Option for Medicare - Froedtert Pharmacy Home Delivery

New for Medicare members, we are adding **Froedtert Home Delivery** as a mail order option, joining with our other preferred mail order option of Express Scripts Home Delivery. **Froedtert Home Delivery** is a Wisconsin-based preferred mail order option with a reputation for excellent customer service. Prescriptions can be e-prescribed to Froedtert by sending to "Froedtert Hospital – 87th Street entrance." Alternatively, providers can fax to 414-805-6513 or by calling the Medication Management Team at 414-805-5690.

### Pharmacy and Therapeutic Changes for January and March 2025

#### New Drug Additions

	Comment	Preferred Brand	Non-Preferred Brand	Preferred Specialty
Kisunla	M <sup>4</sup> , C <sup>1</sup>			
Ohtuvayre	M, C <sup>1</sup>			
Tryvio	M, C <sup>1</sup>			
Cobenfy	PA, QLL			
Ebglyss	M, C <sup>1</sup>			

Livdelzi	M, C <sup>1</sup>				
Neffy	M, C <sup>1</sup>				
Nemluvio	PA, QLL			C <sup>3</sup>	

**C** indicates commercial preferred drug list (PDL) status

**M** indicates Medicare PDL status

**PA** indicates that prior authorization is required

**QL** indicates a quantity limit

**ST** indicates that step therapy is required

Footnotes:

1. Non-Formulary for Medicare and Commercial
2. Non-Formulary for Commercial
3. Non-Formulary for Medicare
4. Medical benefit, CCUM prior authorization for Medicare

### Medicare Quantity Level Limit Updates

Medication	Quantity/Supply
Augtyro 160 mg capsule	Add 60/30 days
Hydrocodone with acetaminophen 2.5-325 mg tablet	Add 360/30 days
Itovebi 3 mg tablet	Add 60/30 days
Itovebi 9 mg tablet	Add 30/30 days
Lumakras 240 mg tablet	Add 120/30 days
Opipza 2 mg, 5 mg, 10 mg film	Change from 30/30 days to 60/30 days
Bimzelx 320 mg/2 ml syringe, autoinjector	4 ml/28 days

Prevymis 120 mg pellets in packet	120/30 days
Prevymis 20 mg pellets in packet	120/30 days
Simlandi 20 mg/0.2 ml syringe	2 syringes/28 days
Simlandi 80 mg/0.8 ml syringe	2 syringes/28 days

---

**Commercial Quantity Level Limit Updates**

<b>Medication</b>	<b>Quantity/Supply</b>
Ocrevus Zunovo 920 mg-23,000 mg	Add 1 vial/180 days
Temazepam 7.5 mg, 15 mg, 22.5 mg, 30 mg capsule	Add 15/fill
Tremfya 200 mg/2 ml pen	Add 1 pen/28 days
Tremfya 200 mg/2 ml syringe	Add 1 syringe/28 days
Adalimumab-adaz(CF) 20 mg/0.2 ml syringe	2 syringes/28 days
Alyftrek 10-50-125 mg tablet	56 tablets/fill
Alyftrek 4-20-50 mg tablet	84 tablets/fill
Bimzelx 320 mg/2 ml syringe, autoinjector	2 ml/56 days

---

Nemluvio 30 mg pen	2 pens/28 days
Simlandi(CF) 40 mg/0.4 ml syringe	2 syringes/28 days

**Prior Authorization Updates**

<b>Policy</b>	<b>Change</b>
FCR PAR_100 Non-Formulary: Xywav	Medicare and Commercial: 1.1.2025 New non-formulary criteria
FCR PAR_102 Non-Formulary: Wakix	Medicare and Commercial: 1.1.2025 New non-formulary criteria
FCR PAR_103 Non-Formulary: Zepbound	Medicare and Commercial: 1.1.2025 New non-formulary criteria
FCR PAR_104 Non-Formulary: Ingrezza	Medicare and Commercial: 1.1.2025 New non-formulary criteria
FCR PAR_105 Non-Formulary: Camzyos	Medicare and Commercial: 1.1.2025 New non-formulary criteria
FCR PAR_106 Non-Formulary: Radicava ORS	Medicare and Commercial: 1.1.2025 New non-formulary criteria

FCR PAR_107 Non-Formulary: Firdapse	Medicare and Commercial: 1.1.2025 New non-formulary criteria
FCR PAR_108 Non-Formulary: Orladeyo	Medicare and Commercial: 1.1.2025 New non-formulary criteria
FCR PAR_109 Non-Formulary: Tyvaso	Medicare and Commercial: 1.1.2025 New non-formulary criteria
FCR PAR_110 Non-Formulary: Jynarque	Medicare and Commercial: 1.1.2025 New non-formulary criteria
FCR PAR_111 Non-Formulary: Samsca	Medicare and Commercial: 1.1.2025 New non-formulary criteria
FCR PAR-112 Orenitram	Medicare and Commercial: 1.1.2025 New non-formulary criteria
PAR-250 Etanercept (Enbrel)	Medicare and Commercial: Medicare: For psoriatic arthritis, removing reference to disease severity, removing pre-requisite medication trials following CMS review. Commercial: Updating criteria to align with ESI's ICCV criteria to align with 1/1/2025.
PAR-287 Tocilizumab (Actemra)	Medicare and Commercial: For Medicare: Removing methotrexate pre-requisite from giant cell arteritis criteria following Dr. Gowing's input and review of current literature. Commercial: Updating to align with ESI's ICCV criteria for 1/1/2025
PAR-303 Individual Family Plan – Diagnosis and Associated Non-Covered Medications	Commercial: Updated to remove GCN and TC column. Updated to note that Excluded drugs will also apply to that drug's biosimilar product.
PAR-337 Excluded/Non-Formulary drugs - Commercial	Commercial: Updating to expand criteria

PAR-400 Sodium Oxybate	Medicare: Updating narcolepsy criteria to clarify that pre-requisite trials apply to adults only
PAR-416 Dupixent (dupilumab)	Medicare and Commercial: Medicare: Updated exclusion criteria following CMS review – considered not consistent with FDA labeling. Updated asthma criteria to reflect FEV1 and FEV1/FVC values that are consistent with pediatric population. Commercial: Updating to align with ESI's ICCV criteria for 1/1/2025
PAR-426 Benralizumab (Fasenra)	Medicare and Commercial: Adding in criteria for new indication of eosinophilic granulomatosis with polyangiitis
PAR-518 Imbruvica (Ibrutinib)	Medicare: Updating to remove step therapy for certain disease states due to CMS review
PAR-570 Benlysta (belimumab)	Medicare and Commercial: Updating to remove exclusion related to dialysis – not supported by FDA labeling per CMS review
PAR-622 Anticonvulsant Therapy	Medicare: Adding in new aripiprazole formulation, Opipta, to prior authorization.
PAR-630 Oncology Products Reviewed by Evicore	Medicare: Adding new oncology products: Itovebi, Vyloy, Ziihera
PAR-633 Subcutaneous Immune Globulin	Medicare: Update to include HyQvia for the CIDP indication due to update in FDA indication
PAR-693 Bimzelx (bimekizumab-bkxz)	Medicare and Commercial: Commercial: Updating to align with ESI's ICCV criteria for 2025
PAR-287 Tocilizumab (Actemra and Tyenne)	Medicare and Commercial: Medicare - Updating to remove FVC requirement on interstitial lung disease criteria following CMS' review.
PAR-400 Sodium Oxybate	Medicare: Updating to remove restriction that modafinil or armodafinil cannot be used in combination with sodium oxybate.

PAR-413 Tremfya (Guselkumab)	Medicare and Commercial: Medicare - Updating Ulcerative Colitis criteria to include Skyrizi as a preferred alternative. CMS review required we remove pre-requisite trials for psoriatic arthritis.
PAR-434 Icatibant	Medicare and Commercial: Updating following CMS' review and updates related to diagnostic criteria and coverage duration.
PAR-483 Risankizumab (Skyrizi)	Medicare and Commercial: Medicare - Updated to include ulcerative colitis indication.
PAR-529 Sandostatin (octreotide acetate)	Medicare: Adding coverage for off-label use of enterocutaneous fistulae
PAR-534 Arikayce (amikacin sulfate liposomal with nebulizer accessories)	Medicare: Updating to remove requirement that sputum culture results need to be within the past 3 months after completing background multidrug regimen.
PAR 630 Oncology Products Reviewed by Evicore	Medicare: Adding in new products: Bizengri, Datroway, Frindovyx, Hercessi, Imkeldi and Opdivo Qvantig
PAR-652 Sodium Phenylbutyrate	Medicare and Commercial: Updating to include enzymatic testing as a way to confirm diagnosis
PAR-667 Xifaxan	Medicare and Commercial: Adding in criteria for off-label small intestinal bacterial overgrowth
PAR-669 Lupron Depot	Medicare: Updating coverage duration for treatment of endometriosis and uterine fibroids to avoid need for reauthorization.
PAR-691 Omvoh (mirikizumab-mrkz subcutaneous)	Medicare and Commercial: Medicare – Updating to include new indication for Crohn's Disease
PAR-693 Bimzelx (bimekizumab-bkxz)	Medicare and Commercial: Medicare - Updating to include criteria for new FDA indication of hidradenitis suppurativa. Commercial: Updated to

	align with ESI ICCV criteria, added new FDA indication for HS
PAR-715 Cobenfy (xanomeline and trospium chloride)	Medicare: New PA
PAR-716 Nemluvio (nemolizumab-ilto)	Medicare: New PA

---

### Contact Network Health Pharmacy Department

A pharmacist at Network Health is always available to help your office staff with any pharmacy-related questions. The pharmacist contact information is listed below.

- General pharmacist [pharmacist@networkhealth.com](mailto:pharmacist@networkhealth.com)
- Beth Coopman [bcoopman@networkhealth.com](mailto:bcoopman@networkhealth.com)
- Jack Kumbalek [jakumbal@networkhealth.com](mailto:jakumbal@networkhealth.com)
- Gary Melis [gmelis@networkhealth.com](mailto:gmelis@networkhealth.com)
- Anna Peterson Sanders [apeterso@networkhealth.com](mailto:apeterso@networkhealth.com)
- Ted Regalia [tregalia@networkhealth.com](mailto:tregalia@networkhealth.com)
- Andy Wheaton [awheaton@networkhealth.com](mailto:awheaton@networkhealth.com)
- Sarah Wilczek [swilczek@networkhealth.com](mailto:swilczek@networkhealth.com)



Preferred Drug List

## Pharmacy Review

If you have questions about the 2024 pharmacy prescription benefits for Network Health members or about resources where members can learn more about patient assistance programs to help cover the cost of medications, contact Gary Melis [gmelis@networkhealth.com](mailto:gmelis@networkhealth.com) or [920-720-1696](tel:920-720-1696). Gary is available for office visits to discuss any pharmacy-related topics with pharmacy staff.

Network Health's most up-to-date Preferred list can be found at [networkhealth.com/look-up-medication](https://networkhealth.com/look-up-medication)